Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press25210.17650/2313-805X-2020-7-1-8-16REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИThe therapeutic potential of curcumin for the treatment of glioblastoma multiformeТерапевтический потенциал куркумина для лечения мультиформной глиобластомыhttps://orcid.org/0000-0001-9626-6847KushnirT. I.КушнирТ. И.
Russian Federation

Build. 15, 24 Kashirskoe Shosse, Moscow 115478; Build. 2, 10 Miklukho-Maklaya St., Moscow 117198

Татьяна Ивановна Кушнир

115478 Москва, Каширское шоссе, 24, стр. 15; 117198 Москва, ул. Миклухо-Маклая, 10, корп. 2

winard2@mail.ruhttps://orcid.org/0000-0002-0154-8604ArnotskayaN. E.АрноцкаяН. Е.
Russian Federation

Build. 15, 24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24, стр. 15

https://orcid.org/0000-0001-7588-1066KudryavtsevI. A.КудрявцевИ. А.
Russian Federation

Build. 15, 24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24, стр. 15

https://orcid.org/0000-0002-0401-9900ShevchenkoV. E.ШевченкоВ. Е.
Russian Federation

Build. 15, 24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24, стр. 15

Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaНИИ канцерогенеза ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииInstitute of Biochemical Technology and Nanotechnology, Peoples’ Friendship University of RussiaИнститут биохимической технологии и нанотехнологии ФГАОУ ВО «Российский университет дружбы народов»15012020718162803202028032020Copyright ©; 2020, Kushnir T.I., Arnotskaya N.E., Kudryavtsev I.A., Shevchenko V.E.Copyright ©; 2020, Кушнир Т.И., Арноцкая Н.Е., Кудрявцев И.А., Шевченко В.Е.2020Kushnir T.I., Arnotskaya N.E., Kudryavtsev I.A., Shevchenko V.E.Кушнир Т.И., Арноцкая Н.Е., Кудрявцев И.А., Шевченко В.Е.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/252

Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly type of primary malignant brain tumor, with a patien’s median survival rate ranging from 12 to 15 months. Over the last fifteen years, the treatment for GBM has included maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide chemotherapy. The low efficacy of mentioned therapies has forced researchers to explore an appropriate alternative or complementary treatment for GBM. It has been shown that curcumin has therapeutic potentials to fight against GBM via affecting on cell proliferation, apoptosis, cell cycle, invasion and angiogenesis pathways. In addition, curcumin possess a synergistic impact with chemotherapeutic agents. Herein, we summarized the current findings on curcumin as potential therapeutic agent in the treatment of GBM.

Мультиформная глиобластома (МГБ), астроцитома IV степени, является наиболее распространенным и смертельно опасным типом первичной злокачественной опухоли головного мозга с медианой выживаемости 12–15 мес. Последние 15 лет терапия МГБ включает максимально безопасную хирургическую резекцию в комбинации с лучевой терапией и адъювантной химиотерапией темозоломидом. Низкая эффективность упомянутых методов лечения вынуждает исследователей искать подходящее альтернативное или дополнительное лечение МГБ. Было показано, что куркумин имеет терапевтический потенциал для борьбы с МГБ, воздействуя на пролиферацию клеток, апоптоз, клеточный цикл, инвазию и ангиогенные сигнальные пути. Кроме этого, куркумин обладает синергическим эффектом с химиотерапевтическими препаратами. Здесь мы суммировали текущие данные о курку мине как потенциальном терапевтическом агенте для лечения МГБ.

curcuminglioblastoma multiformeangiogenesisapoptosisinvasionкуркуминмультиформная глиобластомаангиогенезапоптозинвазия1. Shahcheraghi S.H., Zangui M., Lotfi M. et al. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr Pharm Des 2019;25(3):333–42. DOI: 10.2174/1381612825666190313123704.Shahcheraghi S.H., Zangui M., Lotfi M. et al. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr Pharm Des 2019;25(3):333–42. DOI: 10.2174/1381612825666190313123704.2. Erices J.I., Torres A., Niechi I. et al. Current natural therapies in the treatment against glioblastoma. Phytother Res 2018;32(11):2191–201. DOI: 10.1002/ptr.6170.Erices J.I., Torres A., Niechi I. et al. Current natural therapies in the treatment against glioblastoma. Phytother Res 2018;32(11):2191–201. DOI: 10.1002/ptr.6170.3. Huang B.R., Tsai C.H., Chen C.C. et al. Curcumin promotes connexin 43 degradation and temozolomide-induced apoptosis in glioblastoma cells. Am J Chin Med 2019;47(3):657–74. DOI: 10.1142/S0192415X19500344.Huang B.R., Tsai C.H., Chen C.C. et al. Curcumin promotes connexin 43 degradation and temozolomide-induced apoptosis in glioblastoma cells. Am J Chin Med 2019;47(3):657–74. DOI: 10.1142/S0192415X19500344.4. Arevalo A.T., Erices J.I., Uribe D.A. et al. Current therapeutic alternatives and new perspectives in glioblastoma multiforme. Curr Med Chem 2017;24(25):2781–95. DOI: 10.2174/0929867324666170303122241.Arevalo A.T., Erices J.I., Uribe D.A. et al. Current therapeutic alternatives and new perspectives in glioblastoma multiforme. Curr Med Chem 2017;24(25):2781–95. DOI: 10.2174/0929867324666170303122241.5. Schor N.F. New approaches to pharma-cotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol Ther 2009;122(1):44–55. DOI: 10.1016/j.pharmthera.2009.01.001.Schor N.F. New approaches to pharma-cotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol Ther 2009;122(1):44–55. DOI: 10.1016/j.pharmthera.2009.01.001.6. Mierzwa M.L., Nyati M.K., Morgan M.A. et al. Recent advances in combined modality therapy. Oncologist 2010;15(4):372–81. DOI: 10.1634/theoncologist.2009-S105.Mierzwa M.L., Nyati M.K., Morgan M.A. et al. Recent advances in combined modality therapy. Oncologist 2010;15(4):372–81. DOI: 10.1634/theoncologist.2009-S105.7. Philip-Ephraim E.E., Eyong K.I., Williams U.E. et al. The role of radiotherapy and chemotherapy in the treatment of primary adult high grade gliomas: assessment of patients for these treatment approaches and the common immediate side effects. ISRN Oncol 2012;902178. DOI: 10.5402/2012/902178.Philip-Ephraim E.E., Eyong K.I., Williams U.E. et al. The role of radiotherapy and chemotherapy in the treatment of primary adult high grade gliomas: assessment of patients for these treatment approaches and the common immediate side effects. ISRN Oncol 2012;902178. DOI: 10.5402/2012/902178.8. Klinger N.V., Mittal S. Therapeutic Potential of Curcumin for the Treatment of Brain Tumors. Oxidative Medicine and Cellular Longevity 2016:1–14. DOI: 10.1155/2016/9324085.Klinger N.V., Mittal S. Therapeutic Potential of Curcumin for the Treatment of Brain Tumors. Oxidative Medicine and Cellular Longevity 2016:1–14. DOI: 10.1155/2016/9324085.9. Misso G., Di Martino M.T., De R.G. et al. Mir-34: a new weapon against cancer? Molr Ther Nucl Acid 2014;3(9):e195. DOI:10.1038/mtna.2014.47.Misso G., Di Martino M.T., De R.G. et al. Mir-34: a new weapon against cancer? Molr Ther Nucl Acid 2014;3(9):e195. DOI:10.1038/mtna.2014.47.10. Shah A.H., Bregy A., Heros D.O. et al. Dendritic cell vaccine for recurrent highgrade gliomas in pediatric and adult subjects: clinical trial protocol. Neurosurgery 2013;73(5):863–7. DOI: 10.1227/NEU.0000000000000107.Shah A.H., Bregy A., Heros D.O. et al. Dendritic cell vaccine for recurrent highgrade gliomas in pediatric and adult subjects: clinical trial protocol. Neurosurgery 2013;73(5):863–7. DOI: 10.1227/NEU.0000000000000107.11. Gulati S., Jakola A.S., Johannesen T.B., Solheim O. Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg 2012;78(5):518–26. DOI: 10.1016/j.wneu.2011.12.008.Gulati S., Jakola A.S., Johannesen T.B., Solheim O. Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg 2012;78(5):518–26. DOI: 10.1016/j.wneu.2011.12.008.12. Shabaninejad Z., Pourhanifeh M.H., Movahedpour A. et al. Therapeutic potentials of curcumin in the treatment of glioblstoma. Eur J Med Chem 2020;188:112040. DOI: 10.1016/j.ejmech.2020.112040.Shabaninejad Z., Pourhanifeh M.H., Movahedpour A. et al. Therapeutic potentials of curcumin in the treatment of glioblstoma. Eur J Med Chem 2020;188:112040. DOI: 10.1016/j.ejmech.2020.112040.13. Sherriff J., Tamangani J., Senthil L. et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol 2013;86(1022):20120414. DOI: 10.1259/bjr.20120414.Sherriff J., Tamangani J., Senthil L. et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol 2013;86(1022):20120414. DOI: 10.1259/bjr.20120414.14. Hesari A., Rezaei M., Rezaei M. et al. Effect of curcumin on glioblastoma cells. J Cell Physiol 2019;234(7):10281–8. DOI: 10.1002/jcp.27933.Hesari A., Rezaei M., Rezaei M. et al. Effect of curcumin on glioblastoma cells. J Cell Physiol 2019;234(7):10281–8. DOI: 10.1002/jcp.27933.15. Kunati S.R., Yang S., William B.M., Xu Y. An LC-MS/MS method for simultaneous determination of curcumin, curcumin glucuronide and curcumin sulfate in a phase II clinical trial. J Pharm Biomed Anal 2018;156:189–98. DOI: 10.1016/j.jpba.2018.04.034.Kunati S.R., Yang S., William B.M., Xu Y. An LC-MS/MS method for simultaneous determination of curcumin, curcumin glucuronide and curcumin sulfate in a phase II clinical trial. J Pharm Biomed Anal 2018;156:189–98. DOI: 10.1016/j.jpba.2018.04.034.16. Ahmed T., Gilani A.H. Therapeutic potential of turmeric in Alzheimer’s disease: curcumin or curcuminoids? Phytother Res 2014;28(4):517–25. DOI: 10.1002/ptr.5030.Ahmed T., Gilani A.H. Therapeutic potential of turmeric in Alzheimer’s disease: curcumin or curcuminoids? Phytother Res 2014;28(4):517–25. DOI: 10.1002/ptr.5030.17. Hewlings S., Kalman D. Curcumin: a review of its’ effects on human health. Foods 2017;6(10):pii:E92. DOI: 10.3390/foods6100092.Hewlings S., Kalman D. Curcumin: a review of its’ effects on human health. Foods 2017;6(10):pii:E92. DOI: 10.3390/foods6100092.18. Kotha R.R., Luthria D.L. Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules 2019; 24(16). DOI: 10.3390/molecules24162930.Kotha R.R., Luthria D.L. Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules 2019; 24(16). DOI: 10.3390/molecules24162930.19. Tsuda T. Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives. Food Funct 2018;9(2):705–14. DOI: 10.1039/c7fo01242j.Tsuda T. Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives. Food Funct 2018;9(2):705–14. DOI: 10.1039/c7fo01242j.20. Amalraj A., Pius A., Gopi S. et al. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives – a review. J Tradit Complement Med 2016;7(2):205–33. DOI: 10.1016/j.jtcme.2016.05.005.Amalraj A., Pius A., Gopi S. et al. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives – a review. J Tradit Complement Med 2016;7(2):205–33. DOI: 10.1016/j.jtcme.2016.05.005.21. Deogade S., Ghate S. Curcumin: therapeutic applications in systemic and oral health. Int J Biol Pharm Res 2015;6(4):281–90. DOI: 10.21276/ijbpr.Deogade S., Ghate S. Curcumin: therapeutic applications in systemic and oral health. Int J Biol Pharm Res 2015;6(4):281–90. DOI: 10.21276/ijbpr.22. Kocaadam B., Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2015;57(13):2889–95. DOI: 10.1080/10408398.2015.1077195.Kocaadam B., Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2015;57(13):2889–95. DOI: 10.1080/10408398.2015.1077195.23. Lopresti A.L. Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies. J Psychopharmacol 2017;31(3):287–302. DOI: 10.1177/0269881116686883.Lopresti A.L. Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies. J Psychopharmacol 2017;31(3):287–302. DOI: 10.1177/0269881116686883.24. Prasad S., Gupta S.C., Tyagi A.K. et al. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv 2014;32(6):1053–64. DOI: 10.1016/j.biotechadv.2014.04.004.Prasad S., Gupta S.C., Tyagi A.K. et al. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv 2014;32(6):1053–64. DOI: 10.1016/j.biotechadv.2014.04.004.25. Nelson K.M., Dahlin J.L., Bisson J. et al. The essential medicinal chemistry of curcumin. J Med Chem 2017;60(5):1620–37. DOI: 10.1021/acs.jmedchem.6b00975.Nelson K.M., Dahlin J.L., Bisson J. et al. The essential medicinal chemistry of curcumin. J Med Chem 2017;60(5):1620–37. DOI: 10.1021/acs.jmedchem.6b00975.26. Chen L., Shi L., Wang W., Zhou Y. ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin. Oncotarget 2017;8(26):43237–47. DOI: 10.18632/oncotarget.18018.Chen L., Shi L., Wang W., Zhou Y. ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin. Oncotarget 2017;8(26):43237–47. DOI: 10.18632/oncotarget.18018.27. Luthra P.M., Lal N. Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of glioblastoma. Eur J Med Chem 2016;109:23–35. DOI: 10.1016/j.ejmech.2015.11.049.Luthra P.M., Lal N. Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of glioblastoma. Eur J Med Chem 2016;109:23–35. DOI: 10.1016/j.ejmech.2015.11.049.28. Hosseini A., Hosseinzadeh H. Antidotal or protective effects of Curcuma longa (turmeric) and its active ingredient, curcumin, against natural and chemical toxicities: A review. Biomed Pharmacother 2018;99:411–21. DOI: 10.1016/j.biopha.2018.01.072.Hosseini A., Hosseinzadeh H. Antidotal or protective effects of Curcuma longa (turmeric) and its active ingredient, curcumin, against natural and chemical toxicities: A review. Biomed Pharmacother 2018;99:411–21. DOI: 10.1016/j.biopha.2018.01.072.29. Luo Q., Luo H., Fu H. et al. Curcumin suppresses invasiveness and migration of human glioma cells in vitro by inhibiting HDGF/β-catenin complex. Nan Fang Yi Ke Da Xue Xue Bao 2019;39(8):911–6. DOI: 10.12122/j.issn.1673-4254.2019.08.06.Luo Q., Luo H., Fu H. et al. Curcumin suppresses invasiveness and migration of human glioma cells in vitro by inhibiting HDGF/β-catenin complex. Nan Fang Yi Ke Da Xue Xue Bao 2019;39(8):911–6. DOI: 10.12122/j.issn.1673-4254.2019.08.06.30. Mortezaee K., Salehi E., Mirtavoos-Mahyari H. et al. Mechanisms of apoptosis modulation by curcumin: implications for cancer therapy. J Cell Physiol 2019;234(8):12537–50. DOI: 10.1002/jcp.28122.Mortezaee K., Salehi E., Mirtavoos-Mahyari H. et al. Mechanisms of apoptosis modulation by curcumin: implications for cancer therapy. J Cell Physiol 2019;234(8):12537–50. DOI: 10.1002/jcp.28122.31. Zanotto-Filho A., Braganhol E., Klafke K. et al. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Let 2015;358(2):220–31. DOI: 10.1016/j.canlet.2014.12.044.Zanotto-Filho A., Braganhol E., Klafke K. et al. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Let 2015;358(2):220–31. DOI: 10.1016/j.canlet.2014.12.044.32. Carolina Alves R., Perosa Fernandes R., Fonseca-Santos B. et al. A critical review of the properties and analytical methods for the determination of curcumin in biological and pharmaceutical matrices. Crit Rev Anal Chem 2019;49(2):138–49. DOI: 10.1080/10408347.2018.1489216.Carolina Alves R., Perosa Fernandes R., Fonseca-Santos B. et al. A critical review of the properties and analytical methods for the determination of curcumin in biological and pharmaceutical matrices. Crit Rev Anal Chem 2019;49(2):138–49. DOI: 10.1080/10408347.2018.1489216.33. Dhandapani K.M., Mahesh V.B., Brann D.W. Curcumin suppresses growth and chemoresistance of human glio blastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 2007;102(2):522–38. DOI: 10.1111/j.1471-4159.2007.04633.x.Dhandapani K.M., Mahesh V.B., Brann D.W. Curcumin suppresses growth and chemoresistance of human glio blastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 2007;102(2):522–38. DOI: 10.1111/j.1471-4159.2007.04633.x.34. Trotta T., Panaro M.A., Prifti E. et al. Modulation of biological activities in glioblastoma mediated by curcumin. Nutr Cancer 2019;71(8):1241–53. DOI: 10.1080/01635581.2019.1604978.Trotta T., Panaro M.A., Prifti E. et al. Modulation of biological activities in glioblastoma mediated by curcumin. Nutr Cancer 2019;71(8):1241–53. DOI: 10.1080/01635581.2019.1604978.35. Park K.S., Yoon S.Y., Park S.H. et al. Anti-migration and anti-invasion effects of curcumin via suppression of fascin expression in glioblastoma cells. Brain Tumor Res Treat 2019;7(1):16–24. DOI: 10.14791/btrt.2019.7.e28.Park K.S., Yoon S.Y., Park S.H. et al. Anti-migration and anti-invasion effects of curcumin via suppression of fascin expression in glioblastoma cells. Brain Tumor Res Treat 2019;7(1):16–24. DOI: 10.14791/btrt.2019.7.e28.36. Ghosh S., Banerjee S., Sil P.C. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem Toxicol 2015;83:111–24. DOI: 10.1016/j.fct.2015.05.022.Ghosh S., Banerjee S., Sil P.C. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem Toxicol 2015;83:111–24. DOI: 10.1016/j.fct.2015.05.022.37. Meng X., Cai J., Liu J. et al. Curcumin increases efficiency of γ-irradiation in gliomas by inhibiting Hedgehog signaling pathway. Cell Cycle 2017;16(12):1181–92. DOI: 10.1080/15384101.2017.1320000.Meng X., Cai J., Liu J. et al. Curcumin increases efficiency of γ-irradiation in gliomas by inhibiting Hedgehog signaling pathway. Cell Cycle 2017;16(12):1181–92. DOI: 10.1080/15384101.2017.1320000.38. Saberi-Karimian M., Katsiki N., Caraglia M. et al. Vascular endothelial growth factor: an important molecular target of curcumin. Crit Rev Food Sci Nutr 2019;59(2):299–312. DOI: 10.1080/10408398.2017.1366892.Saberi-Karimian M., Katsiki N., Caraglia M. et al. Vascular endothelial growth factor: an important molecular target of curcumin. Crit Rev Food Sci Nutr 2019;59(2):299–312. DOI: 10.1080/10408398.2017.1366892.39. Wang T.Y., Chen J.X. Effects of curcumin on vessel formation insight into the pro- and antiangiogenesis of curcumin. Evid Based Complement Alternat Med 2019. DOI:10.1155/2019/1390795.Wang T.Y., Chen J.X. Effects of curcumin on vessel formation insight into the pro- and antiangiogenesis of curcumin. Evid Based Complement Alternat Med 2019. DOI:10.1155/2019/1390795.40. Wang X., Deng J., Yuan J. et al. Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells. Int J Oncol 2017;51(2):467–77. DOI: 10.3892/ijo.2017.4037.Wang X., Deng J., Yuan J. et al. Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells. Int J Oncol 2017;51(2):467–77. DOI: 10.3892/ijo.2017.4037.41. Schnekenburger M., Dicato M., Diederich M.F. Anticancer potential of naturally occurring immunoepigenetic modulators: a promising avenue? Cancer 2019;125(10):1612–28. DOI: 10.1002/cncr.32041.Schnekenburger M., Dicato M., Diederich M.F. Anticancer potential of naturally occurring immunoepigenetic modulators: a promising avenue? Cancer 2019;125(10):1612–28. DOI: 10.1002/cncr.32041.42. Su C.C., Wang M.J., Chiu T.L. The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma. Int J Mol Med 2010;26(2):217–24. DOI: 10.3892/ijmm_00000455.Su C.C., Wang M.J., Chiu T.L. The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma. Int J Mol Med 2010;26(2):217–24. DOI: 10.3892/ijmm_00000455.43. Maiti P., Scott J., Sengupta D. et al. Curcumin and solid lipid curcumin particles induce autophagy, but inhibit mitophagy and the PI3K-Akt/mTOR pathway in cultured glioblastoma cells. Int J Mol Sci 2019;20(2). DOI: 10.3390/ijms20020399.Maiti P., Scott J., Sengupta D. et al. Curcumin and solid lipid curcumin particles induce autophagy, but inhibit mitophagy and the PI3K-Akt/mTOR pathway in cultured glioblastoma cells. Int J Mol Sci 2019;20(2). DOI: 10.3390/ijms20020399.44. Sordillo L.A., Sordillo P.P., Helson L. Curcumin for the treatment of glioblastoma. Anticancer Res 2015;35(12):6373–8.Sordillo L.A., Sordillo P.P., Helson L. Curcumin for the treatment of glioblastoma. Anticancer Res 2015;35(12):6373–8.45. Yin H., Zhou Y., Wen C. et al. Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. Oncol Rep 2014;32(4):1610–6. DOI: 10.3892/or.2014.3342.Yin H., Zhou Y., Wen C. et al. Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. Oncol Rep 2014;32(4):1610–6. DOI: 10.3892/or.2014.3342.46. Gersey Z.C., Rodriguez G.A., Barbarite E. et al. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer 2017;17(1):99. DOI: 10.1186/s12885-017-3058-2.Gersey Z.C., Rodriguez G.A., Barbarite E. et al. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer 2017;17(1):99. DOI: 10.1186/s12885-017-3058-2.47. Hossain M., Banik N.L., Ray S.K., Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int 2012;61(7):1102–13. DOI: 10.1016/j.neuint.2012.08.002.Hossain M., Banik N.L., Ray S.K., Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int 2012;61(7):1102–13. DOI: 10.1016/j.neuint.2012.08.002.48. Soleimani V., Sahebkar A., Hosseinzadeh H. Turmeric (Curcuma longa) and its major constituent(curcumin) as nontoxic and safe substances: review. Phytother Res 2018;32(6):985–95. DOI: 10.1002/ptr.6054.Soleimani V., Sahebkar A., Hosseinzadeh H. Turmeric (Curcuma longa) and its major constituent(curcumin) as nontoxic and safe substances: review. Phytother Res 2018;32(6):985–95. DOI: 10.1002/ptr.6054.49. Devassy J.G., Nwachukwu I.D., Jones P.J. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev 2015;73(3):155–65. DOI: 10.1093/nutrit/nuu064.Devassy J.G., Nwachukwu I.D., Jones P.J. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev 2015;73(3):155–65. DOI: 10.1093/nutrit/nuu064.50. Schneider C., Gordon O.N., Edwards R.L. et al. Degradation of curcumin: from mechanism to biological implications. J Agric Food Chem 2015;63(35):7606–14. DOI: 10.1021/acs.jafc.5b00244.Schneider C., Gordon O.N., Edwards R.L. et al. Degradation of curcumin: from mechanism to biological implications. J Agric Food Chem 2015;63(35):7606–14. DOI: 10.1021/acs.jafc.5b00244.51. Priyadarsini K.I. The chemistry of curcumin: from extraction to therapeutic agent. Molecules 2014;19(12):20091–112. DOI: 10.3390/molecules191220091.Priyadarsini K.I. The chemistry of curcumin: from extraction to therapeutic agent. Molecules 2014;19(12):20091–112. DOI: 10.3390/molecules191220091.52. Hussain Z., Thu H.E., Ng S.F. et al. Nanoencapsulation, an efficient and promising approach to maximize wound healing efficacy of curcumin: a review of new trends and state-of-the-art. Colloids Surf B Biointerfaces 2017;150:223–41. DOI: 10.1016/j.colsurfb.2016.11.036.Hussain Z., Thu H.E., Ng S.F. et al. Nanoencapsulation, an efficient and promising approach to maximize wound healing efficacy of curcumin: a review of new trends and state-of-the-art. Colloids Surf B Biointerfaces 2017;150:223–41. DOI: 10.1016/j.colsurfb.2016.11.036.